ATE361096T1 - Antikörper zur modulierung der upa/upar interaktion und deren verwendungen - Google Patents
Antikörper zur modulierung der upa/upar interaktion und deren verwendungenInfo
- Publication number
- ATE361096T1 ATE361096T1 AT02710810T AT02710810T ATE361096T1 AT E361096 T1 ATE361096 T1 AT E361096T1 AT 02710810 T AT02710810 T AT 02710810T AT 02710810 T AT02710810 T AT 02710810T AT E361096 T1 ATE361096 T1 AT E361096T1
- Authority
- AT
- Austria
- Prior art keywords
- upar
- upa
- modulating
- antibodies
- interaction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26319801P | 2001-01-25 | 2001-01-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE361096T1 true ATE361096T1 (de) | 2007-05-15 |
Family
ID=23000794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02710810T ATE361096T1 (de) | 2001-01-25 | 2002-01-22 | Antikörper zur modulierung der upa/upar interaktion und deren verwendungen |
Country Status (7)
Country | Link |
---|---|
US (2) | US7737256B2 (de) |
EP (1) | EP1365797B1 (de) |
AT (1) | ATE361096T1 (de) |
AU (1) | AU2002229721A1 (de) |
DE (1) | DE60219888T2 (de) |
ES (1) | ES2282397T3 (de) |
WO (1) | WO2002058714A2 (de) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7074891B2 (en) | 2003-02-07 | 2006-07-11 | Posco | Leukocyte stimulating peptides |
AU2006208969A1 (en) * | 2005-01-31 | 2006-08-03 | Fondazione Centro San Raffaele Del Monte Tabor | Therapeutic peptides derived from urokinase plasminogen activator receptor |
EP1856155B1 (de) | 2005-03-11 | 2011-08-24 | Wilex AG | Monoklonale antikörper und immundetektionsprüfung spezifisch für das chemotaktische epitop des urokinase-plasminogenaktivator-rezeptors |
ITMI20061607A1 (it) * | 2006-08-09 | 2008-02-10 | Maria Vincenza Carriero | Peptidi con attivita farmacologica |
EP2117571B1 (de) | 2006-12-08 | 2017-03-08 | Monopar Therapeutics Inc. | Plasminogen-aktivator-rezeptor-epitop vom urokinase-typ |
US8815519B2 (en) * | 2006-12-22 | 2014-08-26 | Hvidovre Hospital | Method for predicting cancer and other diseases |
WO2008104857A2 (en) * | 2007-02-26 | 2008-09-04 | Universite De Lausanne | Method for predicting susceptibility of hiv infection |
US20160169910A1 (en) * | 2013-08-01 | 2016-06-16 | Rush University Medical Center | Non-Glycosylated suPar Biomarkers and Uses Thereof |
JP2022513317A (ja) * | 2018-09-28 | 2022-02-07 | ヨッヘン ライザー | suPARならびに急性腎傷害の予測および治療 |
CN113975381A (zh) * | 2020-07-26 | 2022-01-28 | 刘建宁 | 尿激酶原及其变体在病毒引起的凝血疾病中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990012091A1 (en) * | 1989-04-07 | 1990-10-18 | Cancerforskningsfondet Af 1989 | Urokinase-type plasminogen activator receptor |
JP2852192B2 (ja) | 1994-07-08 | 1999-01-27 | カンセアフォースクニングスフォンデン・アフ・1989(フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンセアフォースクニング) | uPARのドメイン2+3のuPA結合部位および抗体 |
WO1996013160A1 (en) | 1994-11-01 | 1996-05-09 | New England Deaconess Hospital | Use of urokinase-type plasminogen activators to inhibit hiv infectivity |
ES2224378T3 (es) * | 1997-03-20 | 2005-03-01 | Fondazione Centro San Raffaele Del Monte Tabor | Peptidos mimetizadores de upar. |
US6077508A (en) | 1998-03-23 | 2000-06-20 | American Diagnostica Inc. | Urokinase plasminogen activator receptor as a target for diagnosis of metastases |
DE60035793T2 (de) | 1999-11-25 | 2008-04-30 | Jesper Eugen-Olsen | Verfahren zur diagnose oder prognose einer hiv infektion in einem patienten |
-
2002
- 2002-01-22 DE DE60219888T patent/DE60219888T2/de not_active Expired - Lifetime
- 2002-01-22 AT AT02710810T patent/ATE361096T1/de active
- 2002-01-22 WO PCT/EP2002/000603 patent/WO2002058714A2/en active IP Right Grant
- 2002-01-22 US US10/470,245 patent/US7737256B2/en not_active Expired - Fee Related
- 2002-01-22 ES ES02710810T patent/ES2282397T3/es not_active Expired - Lifetime
- 2002-01-22 AU AU2002229721A patent/AU2002229721A1/en not_active Abandoned
- 2002-01-22 EP EP02710810A patent/EP1365797B1/de not_active Expired - Lifetime
-
2010
- 2010-04-06 US US12/754,626 patent/US20110027285A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE60219888T2 (de) | 2008-01-17 |
US7737256B2 (en) | 2010-06-15 |
US20110027285A1 (en) | 2011-02-03 |
ES2282397T3 (es) | 2007-10-16 |
WO2002058714A2 (en) | 2002-08-01 |
EP1365797B1 (de) | 2007-05-02 |
DE60219888D1 (de) | 2007-06-14 |
US20040115190A1 (en) | 2004-06-17 |
WO2002058714A3 (en) | 2002-10-24 |
AU2002229721A1 (en) | 2002-08-06 |
EP1365797A2 (de) | 2003-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE385806T1 (de) | Fusionsproteine | |
BR0111125A (pt) | Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos | |
MEP31508A (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
DK0804236T3 (da) | Anvendelse af anti-TNF-antistoffer som lægemidler til behandling af sygdomme, som involverer forhøjede interleukin-6-serumniveauer | |
PT1543011E (pt) | Composto de tienopirrolilo e furanopirrolilo e sua utilizacao como ligandos do receptor h4 da histamina | |
CO5690537A2 (es) | Formas solidas de anticuerpos anti-egfr | |
TW200514790A (en) | Bispecific antibody substituting for functional protein | |
CY1108765T1 (el) | ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2 | |
DE60118544D1 (de) | Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren | |
NO20041917L (no) | Spesifikke midler som binder humant angiopoietin-2 | |
DK1287364T3 (da) | Diagnostisk og terapi til makulære degenerationsrelaterede lidelser | |
ATE361096T1 (de) | Antikörper zur modulierung der upa/upar interaktion und deren verwendungen | |
DE60108857D1 (de) | Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren | |
DE60018085D1 (de) | Prozess zum Screening von Molekülen, die spezifisch an die NEP-Bindungsstelle des QHNPR-pentapeptides binden | |
CY1111371T1 (el) | Αντισωματα bag3 για χρηση σε ερευνα, διαγνωση και θεραπεια ασθενειων που σχετιζονται με κυτταρικο θανατο | |
BR0313792A (pt) | Utilização de proteìna de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento | |
ATE431405T1 (de) | Tnf-rezeptor-ähnliche moleküle und deren anwendungen | |
UY27841A1 (es) | Amidas de ácidos 2-heteroarilcarboxílicos | |
DE69534551D1 (de) | Neue methode zum auffindenund bewerten biologisch aktiver moleküle | |
SE0102147D0 (sv) | New methods | |
ATE416756T1 (de) | Methoden zur verwendung von lamellaren körpern für therapeutische zwecke | |
ATE210460T1 (de) | Zusammensetzungen, welche adp-ribosyltransferase- aktivität aufweisen und methoden für ihre herstellung und die verwendung derselben | |
ATE309371T1 (de) | Protein mit dnase-aktivität | |
CY1110278T1 (el) | Μεθοδος διαλογης παραγοντων ικανων να θεραπευουν την παχυσαρκια | |
ATE298244T1 (de) | Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1365797 Country of ref document: EP |